{
    "nctId": "NCT00369109",
    "briefTitle": "Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid Tumors",
    "officialTitle": "Collection of Skin Biopsy With Hair Follicles as Surrogate to Develop Biomarker Assays From Patients With Advanced Solid Tumor Malignancies Receiving Either Single Agent Weekly Irinotecan or Gemcitabine",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Colorectal Cancer, Pancreatic Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Level of p-Chk1 and phospho-histone 2AX (p-H2AX) and possibly downstream pathway markers in hair follicles from skin biopsies of patients treated with gemcitabine hydrochloride or irinotecan hydrochloride for advanced solid tumors",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Diagnosis of advanced solid tumor malignancy (preferably colorectal, pancreatic, or breast cancer)\n* Scheduled to receive a standard dose, weekly regimen of either irinotecan hydrochloride or gemcitabine hydrochloride\n\nPATIENT CHARACTERISTICS:\n\n* Not specified\n\nPRIOR CONCURRENT THERAPY:\n\n* No DNA-damaging agent within the past 13 days",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}